)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Alumis
Alumis (ALMS) investor relations material
Alumis Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary12 Feb, 2026
Key clinical results and milestones
Phase III results for envudeucitinib in psoriasis showed strong PASI score reductions, with PASI 90 and 100 rates at week 24 of about 65% and over 40%, respectively.
Fast onset of action observed, with separation in PASI scores as early as week 4 and a safety profile consistent with previous data.
Abstract submitted for AAD, aiming to present more detailed data and quality of life outcomes.
NDA filing planned for the second half of the year, pending completion of the withdrawal study and long-term data.
Additional data, including 48-week and biomarker results, expected later this year.
Market dynamics and commercial strategy
Oral drugs currently have a higher patient share than injectables in psoriasis, with a trend toward further expansion as patients prefer oral options.
Market research indicates 75% of patients would prefer a pill over injectables or topicals.
Expectation that oral market will expand, with injectables becoming more of a backup therapy.
Commercial infrastructure is in place for launch, but a partnership is likely for global expansion and multiple indications.
Pipeline and future indications
SLE (lupus) is a key upcoming indication, with phase IIb pivotal trial results expected in Q3; trial design emphasizes patient selection, steroid tapering, and robust data monitoring.
Success in lupus defined as achieving efficacy similar to anifrolumab (about 15% placebo-adjusted delta on BICLA).
Additional indications under consideration include psoriatic arthritis, interferon-driven diseases, and IBD, with decisions influenced by upcoming competitor and internal data.
Brain-penetrant TYK2 inhibitor for MS to begin studies in the first half of the year, with potential for other CNS and autoimmune indications.
Rationale for partnership over solo commercialization?
How LUMA design minimizes placebo and ensures success?
What drives TYK2 pipeline expansion beyond SLE/Pso?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Alumis earnings date
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb, 2026
Alumis
Next Alumis earnings date
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for autoimmune diseases. The company's research primarily targets allosteric inhibitors of tyrosine kinase 2 (TYK2), with potential applications in treating conditions like psoriasis, systemic lupus erythematosus, and neuroinflammatory disorders. Alumis employs a precision medicine approach to its drug development process, aiming to create targeted therapies for specific immune-related conditions. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage